spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Phenomenex Introduces bioZen Series for Characterization of Biotherapeutics


Torrance, Calif. (April 16, 2018) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces bioZen – a new series of LC solutions for bioseparations in pharmaceutical, biopharmaceutical and academic research. The series encompasses both proven and entirely new media spanning two particle platforms – core-shell and thermally modified fully porous – along with new biocompatible titanium hardware. The initial bioZen product line features seven chemistries for the UHPLC and HPLC characterization of biotherapeutics such as monoclonal antibodies, antibody-drug conjugates and biosimilars. The offering includes specific LC chemistries for the analysis of aggregates and total mAb, intact mass and fragments, peptide mapping and quantitation and glycan mapping.

As an added benefit, all bioZen media, particle sizes and phases are available in Phenomenex’s new biocompatible titanium hardware, which minimizes secondary reactions, carryover and other recovery issues to provide better overall reproducibility than stainless steel hardware. It also minimizes the amount of time typically spent on column priming and does not interfere with protein or peptide integrity.

The bioZen thermally modified fully porous media is produced with Phenomenex’s proprietary post-synthetic thermal treatment process, which improves particle mechanical strength and inertness, providing significantly better peak shape and fewer unwanted secondary interactions than traditional LC media. The thermally modified media pairs well with high-efficiency bioZen Core-Shell Technology media which delivers increased resolution and sensitivity in shorter retention time windows. Both particle platforms undergo stringent QC testing to ensure consistent high quality, while all individual bioZen columns have QC protocols for specific biologic applications to confirm product performance and reproducibility.

"The bioZen series springs from our close work with customers who wanted a comprehensive product offering to cover all of their bioseparations needs," explains Simon Lomas, senior manager of global product marketing for Phenomenex. "This is an exciting and growing portfolio of novel particles, chemistries and biocompatible hardware, supported by our industry gurus, that all combine to help our customers overcome the many challenges associated with the characterization of biologics."

For more information, visit the bioZen web experience. http://biozenbioseparations.com/?utm_campaign=2018%20%20biozen%20launch&utm_source=ebr&utm_medium=advertising&utm_content=press_release



 

For more information regarding this article please contact:
Phenomenex Press Room
Tel: (310) 212-0555 (USA)
Email:
pressroom@phenomenex.com

 

 
Print this page
Send to a friend
   
spacer
News and Press Releases

Charles River to Present Collaborative Methods at Neuroscience 2018

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California.
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement